Sentinel lymph node biopsy in head and neck tumors: current status from the standpoint of evidence-based medicine. The role of radioisotope diagnostics (literature review)
https://doi.org/10.18705/3034-7270-2025-1-2-112-117
Abstract
The article provides an overview of recent publications on the clinical efficacy, safety, and technological aspects of radionuclide sentinel lymph node biopsy in patients with early forms of squamous cell carcinoma of the head and neck. The results of four randomized trials and a large meta-analysis in 2022, data from systematic reviews in 2023–2024, prospective cohorts from Europe and Asia, as well as a series of observations performed using the 99mTc human albumin nanocolloid ("Nanotope") were analyzed. A separate section discusses the physico-chemical and clinical advantages of the radionuclide method in comparison with alternative tracers.
About the Authors
S. P. Dmitriev
Nizhny Novgorod Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
Dmitriev Sergey P. – Head of the 9th Oncology Department of Head and Neck Tumors
Nizhny Novgorod
M. D. Ter-Ovanesov
Nizhny Novgorod Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
Ter-Ovanesov Mikhail D. – Doctor of Medical Sciences, Professor, Deputy Chief Physician
Nizhny Novgorod
A. A. Kazakov
Nizhny Novgorod Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
Kazakov Aleksey A. – Head of the 2nd Inpatient Department
Nizhny Novgorod
T. V. Burova
Nizhny Novgorod Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
Burova Tatyana V. – Head of the Radionuclide Diagnostics Department
Nizhny Novgorod
V. I. Aleksina
Nizhny Novgorod Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
Aleksina Valeria I. – Oncologist, Department of Oncology of Head and Neck Tumors
Nizhny Novgorod
N. M. Maslov
Nizhny Novgorod Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
Maslov Nikita M. – Oncologist, Department of Oncology of Head and Neck Tumors
Nizhny Novgorod
References
1. Amit M., Yen T.C., Liao C.T., et al. Clinical nodal stage is a significant predictor of outcome in patients with oral cavity squamous cell carcinoma and pathologically negative neck metastases: results of the international consortium for outcome research. Ann Surg Oncol. 2013;20(11):3575–81. DOI: 10.1245/s10434-013-3044-0
2. Peters T.T., Senft A., Hoekstra O.S., et al. Pretreatment screening on distant metastases and head and neck cancer patients: validation of risk factors and influence on survival. Oral Oncol. 2015;51(3):267–71. DOI: 10.1016/j.oraloncology.2014.12.006.
3. D’Cruz A.K., Vaish R., Kapre N., et al. Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med. 2015;373(6):521–529.
4. Gupta T., Maheshwari G., Kannan S., et al. Systematic review and meta-analysis of randomized controlled trials comparing elective neck dissection versus sentinel lymph node biopsy in early-stage node-negative oral and/or oropharyngeal SCC. Oral Oncol. 2022;124:105642.
5. Garrel R., Poissonnet G., Fakhry N., et al. Sentinel node biopsy versus neck node dissection in operable cT1-T2N0 oral and oropharyngeal cancer (Senti-MERORL): phase III equivalence trial. J Clin Oncol. 2020;38(32):3673–3682.
6. Ionna F., Pavone E., Aversa C., et al. Sentinel Lymph Node Biopsy (SLNB) for Early-Stage Head and Neck Squamous-Cell Carcinoma of the Tongue: Twenty Years of Experience at I.N.T. "G.Pascale". Cancers (Basel). 2024;16(6):1153.
7. Govers T.M., Hannink G., Merkx M.A.W., et al. Rovers Sentinel node biopsy for squamous cell carcinoma of the oral cavity and oropharynx: a diagnostic meta-analysis. Oral Oncol. 2013;49(8):726–732.
8. Civantos F.J., Russell J., Lai S.Y., et al. Prospective multi-institutional trial of SLNB in cN0 early-stage oral cavity cancer. Cancer. 2022;128(14):2680–2689.
9. Cramer J.D., Lai S.Y. Sentinel node biopsy: high-tech method of predicting neck status – NRG-HN006 rationale. ENT Today. 2021;40(7):16–18.
10. Tartaglione G. Advantages of the intradermal lymphoscintigraphy. World J Radiol. 2024;16(7):241–246.
11. Cusnir R., Leresche M., Pilloud C., Straub M. An investigation of aspects of radiochemical purity of 99mTc-labelled human serum albumin nanocolloid. EJNMMI Radiopharmacy and Chemistry. 2021;6:35.
12. Miura K., Kawakita D., Oze I., et al. Predictive factors for false negatives following sentinel lymph node biopsy in early oral cavity cancer. Sci Rep. 2022;12(1):6917. DOI: 10.1038/s41598-022-10594-1.
13. Kang Y.J., Kang M.J., Ahn H.S., Hwang S.H. Comparison of SLNB and END for early oral cavity SCC: systematic review and meta-analysis. J Laryngol Otol. 2023;137(6):599–607.
14. van Hinte G., Wetzels J.G.H., Merkx M.A.W., et al. Effect of elective neck dissection versus sentinel lymph node biopsy on shoulder morbidity and HR-QoL in oral cavity cancer: longitudinal study. Support Care Cancer. 2024;32(5):2553–2564.
15. Schilling C., Stoeckli S.J., Haerle S.K., et al. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur J Cancer. 2024; 92:2777–2784.
16. Lai S.Y., Torres-Saavedra P.A., Dunlap N.E., et al. NRG-HN006 protocol: randomized Phase II/III trial of SLNB versus END for early-stage oral cavity cancer. NRG Oncology. 2021;39(15):TPS6093-TPS6093. DOI:10.1200/JCO.2021.39.15_suppl.TPS6093.
17. Giammarile F., Schilling C., Gnanasegaran G., et al. EANM practical guidelines for SLN localisation in oral cavity SCC. Eur J Nucl Med Mol Imaging. 2019;46(3):623–637.
18. Instructions for use 99ᵐTc "Nanotop". RU No. RZN2014/1389 (ed. 14.08.2023). (In Russ.)
19. Krivitsky P.I. Innovations in oncoradiology: radiopharmaceuticals are becoming more effective and safer. MedTech. 2020. Aviable at: https://himedtech.ru/articles/innovatsii-v-onkoradiologii-radiofarmpreparaty-stanovyatsya-effektivnee-i-bezopasnee.html (accessed: 12.07.2025) (In Russ.).
20. Sagynbekova G., Dzhunushaliev K. Cervical Lymph Node Dissection for Head and Neck Cancer (Literature Review). Bulletin of Science and Practice. 2024;(3):357–372. (In Russ.)
21. Szczygielski K., Zhang X., Fang Q., et al. SLNB in cT1-2N0 minor salivary gland cancer of the oral cavity. BMC Cancer. 2024;24:1349.
22. Yu X., Fang Q., Du W., et al. Sentinel lymph node biopsy benefits cN0 parotid cancer neck management. Sci Rep. 2019;9:44790.
23. Gelfand I.M., Kropotov M.A., Isaeva M.T., Podvyaznikov S.O. The importance in clinical practice of the signal lymph node biopsy in squamous cell carcinoma of the head and neck. Opukholi golovy i shei = Head and Neck Tumors. 2023;13(4):116–123. DOI: 10.17650/2222-1468-2023-13-4-116-123. (In Russ.)
Review
For citations:
Dmitriev S.P., Ter-Ovanesov M.D., Kazakov A.A., Burova T.V., Aleksina V.I., Maslov N.M. Sentinel lymph node biopsy in head and neck tumors: current status from the standpoint of evidence-based medicine. The role of radioisotope diagnostics (literature review). Russian surgical journal. 2025;1(2):112-117. (In Russ.) https://doi.org/10.18705/3034-7270-2025-1-2-112-117
Views:
267
JATS XML
Email this article 